In the equity market, it is generally good to keep one eye on risk management. But there are times when it becomes a must-do. We are curren...

Given the state of the market these days, it would be wise to be selective. Not only in terms of stocks, but also in terms of sectors. For ...

As global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...

India's drug companies face a tough race in the global biologics market. China is quickly becoming a leader in biotech supply chains. India...

Dr Reddy's Laboratories is strategically shifting focus towards biosimilars and innovation. The company is increasing investment in biosimi...

Biocon's Kiran Mazumdar-Shaw suggests a new drug approval system. The Indian Council of Medical Research would handle scientific reviews fo...

Gland Pharma on Monday reported 12 per cent year-on-year increase in profit after tax (PAT) at Rs 184 crore for the September quarter, aide...

With a clear indication that no additional or special tariff will be imposed by the US on generic drugs, there is a sense of relief among I...

Anthem Biosciences' Rs 3,395 crore IPO will open on July 14 as a complete Offer for Sale by promoters and investors. The Bengaluru-based CR...

Indian CDMOs are strategically expanding through acquisitions in the US and Europe, driven by global pharma's nearshoring trend and a desir...

Let’s accept the fact that we are likely to be dealing with volatility for the next four years. Both in the real world and in the global an...

Anthem Biosciences, a CRDMO, has filed for a Rs 3,395 crore IPO. The offer comprises an OFS by promoters and investors, including True Nort...

Anthem Biosciences has filed its DRHP for an IPO. The issue comprises an offer for sale of up to Rs 3,395 crore by promoters and investors....

The Jammu and Kashmir government will undertake various welfare schemes. The government will provide free electricity and improve the energ...

OneSource, a TPG Growth-backed specialty pharma CDMO, is in talks with investors to raise $200 million. The company, formerly Stelis Biopha...

While they clubbed together, the operating matrix of a pharma company making drugs and hospital and a diagnostic company are very different...

Citing a number of studies published in leading medical journals over the last two decades, he said that by and large the inference is that...